SI2850070T1 - Benzo (1,3) dioxin derivatives and their use as LPAR5 antagonists - Google Patents

Benzo (1,3) dioxin derivatives and their use as LPAR5 antagonists Download PDF

Info

Publication number
SI2850070T1
SI2850070T1 SI201330853T SI201330853T SI2850070T1 SI 2850070 T1 SI2850070 T1 SI 2850070T1 SI 201330853 T SI201330853 T SI 201330853T SI 201330853 T SI201330853 T SI 201330853T SI 2850070 T1 SI2850070 T1 SI 2850070T1
Authority
SI
Slovenia
Prior art keywords
alkyl
benzo
group
carboxylic acid
dicyclohexyl
Prior art date
Application number
SI201330853T
Other languages
English (en)
Slovenian (sl)
Inventor
Marc Nazare
Detlef Kozian
Martin Bossart
Werngard Czechtizky
Andreas Evers
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of SI2850070T1 publication Critical patent/SI2850070T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI201330853T 2012-05-18 2013-05-16 Benzo (1,3) dioxin derivatives and their use as LPAR5 antagonists SI2850070T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305553 2012-05-18
PCT/EP2013/060172 WO2013171318A1 (en) 2012-05-18 2013-05-16 Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists
EP13723767.3A EP2850070B1 (en) 2012-05-18 2013-05-16 Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists

Publications (1)

Publication Number Publication Date
SI2850070T1 true SI2850070T1 (en) 2018-01-31

Family

ID=48468297

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330853T SI2850070T1 (en) 2012-05-18 2013-05-16 Benzo (1,3) dioxin derivatives and their use as LPAR5 antagonists

Country Status (16)

Country Link
US (1) US9221784B2 (enExample)
EP (1) EP2850070B1 (enExample)
JP (1) JP6238970B2 (enExample)
KR (1) KR20150016304A (enExample)
CN (1) CN104302633B (enExample)
AU (1) AU2013261719B2 (enExample)
BR (1) BR112014028189A2 (enExample)
CA (1) CA2871545A1 (enExample)
ES (1) ES2649438T3 (enExample)
IL (1) IL235219A (enExample)
MX (1) MX354521B (enExample)
PL (1) PL2850070T3 (enExample)
RU (1) RU2647727C2 (enExample)
SG (1) SG11201407216YA (enExample)
SI (1) SI2850070T1 (enExample)
WO (1) WO2013171318A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200215085A1 (en) * 2017-07-19 2020-07-09 Uti Limited Partnership Method to Abate Acute Airway Hypersensitivity and Asthma Attacks
KR20250140741A (ko) 2024-03-19 2025-09-26 경북대학교 산학협력단 알룰로스를 포함하는 혈전 예방 또는 개선용 조성물 및 이의 이용

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4056540A (en) 1974-01-01 1977-11-01 Bristol-Myers Company 4-Phenyl-1,3-benzodioxans
US4056450A (en) 1975-06-30 1977-11-01 M & T Chemicals Inc. Continuous detinning system
FR2424914A2 (fr) * 1978-05-03 1979-11-30 Roussel Uclaf Nouveaux derives de (1-3) benzodioxine, un procede pour leur preparation et leur application comme medicaments
SE445553B (sv) * 1978-05-03 1986-06-30 Roussel Uclaf /4h/-1,3-bensodioxan-2-karboxylsyraderivat
GB8310407D0 (en) * 1982-05-12 1983-05-25 Ici Plc 1 3 - dioxan -5- ylalkenoic acids
FR2704857B1 (fr) * 1993-05-07 1995-06-23 Adir Nouvelles benzodioxines substituées, leur procédé de préparation et les compositions pharmaceutiques les contenant.
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
CN101124226A (zh) * 2004-05-07 2008-02-13 记忆药物公司 1h-吲唑、苯并噻唑、1,2-苯并异噁唑、1,2-苯并异噻唑和色酮以及它们的制备和用途
WO2010042600A2 (en) * 2008-10-08 2010-04-15 The Uab Research Foundation Photo-activatable therapeutic agents and methods of using

Also Published As

Publication number Publication date
IL235219A (en) 2017-03-30
EP2850070B1 (en) 2017-08-23
KR20150016304A (ko) 2015-02-11
RU2014151240A (ru) 2016-07-10
BR112014028189A2 (pt) 2017-06-27
MX354521B (es) 2018-03-08
AU2013261719A1 (en) 2014-12-18
ES2649438T3 (es) 2018-01-12
WO2013171318A1 (en) 2013-11-21
MX2014014012A (es) 2015-02-12
CN104302633B (zh) 2016-09-07
CA2871545A1 (en) 2013-11-21
SG11201407216YA (en) 2014-12-30
PL2850070T3 (pl) 2018-01-31
JP2015517515A (ja) 2015-06-22
RU2647727C2 (ru) 2018-03-19
AU2013261719B2 (en) 2017-07-27
US20150111889A1 (en) 2015-04-23
CN104302633A (zh) 2015-01-21
EP2850070A1 (en) 2015-03-25
JP6238970B2 (ja) 2017-11-29
US9221784B2 (en) 2015-12-29

Similar Documents

Publication Publication Date Title
TWI827646B (zh) Ptpn11抑制劑
JP5997709B2 (ja) Ｍｓｔ１キナーゼ阻害剤及びその使用方法
JP6461118B2 (ja) ブロモドメイン阻害剤としての新規の置換された二環式化合物
CN106255689B (zh) 杂芳基syk抑制剂
JP7290627B2 (ja) Ａｔｒキナーゼの複素環式阻害剤
JP7159307B2 (ja) Ａｔｒキナーゼの複素環式阻害剤
JP6500037B2 (ja) 二環式ピラゾロン化合物および使用方法
BR112021008969A2 (pt) compostos e composições para tratar condições as-sociadas à atividade de nlrp
WO2012087938A1 (en) Quinazolinone derivatives as antiviral agents
EP2400962A1 (de) Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
KR20190137843A (ko) 단백질 인산화효소 억제제로서의 1h-이미다조[4,5-h]퀴나졸린 화합물
CN113214287A (zh) Hpk1抑制剂及其使用方法
CA2918813A1 (en) Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinases
AR058919A1 (es) Compuestos de heteroarilo biciclicos como inhibidores de pde10, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades del snc.
EP3197872B1 (de) (2h)-2-oxopyridine als faktor xia-inhibitoren zur behandlung von thrombotischen erkrankungen
KR20160093062A (ko) Pi3k 억제제 및 btk 억제제의 치료적 조합
NZ567151A (en) Pyrazolo [1,5 -A] pyrimidine derivatives and their use for inhibiting Checkpoint kinases
WO2004041814A1 (en) Heteroaryl-pyramidine derivatives as jak inhibitors
BRPI0418082B1 (pt) Derivados de tiazol úteis como antagonistas de receptor de adenosina A2A
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
JP7348897B2 (ja) 抗菌性化合物
CA3005918A1 (en) Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
AU2021324542A1 (en) Method and compound for use, in treating and/or preventing netosis
KR20170055531A (ko) 에스지씨 자극제
WO2014164409A1 (en) Inhibitors of human immunodeficiency virus replication